Track topics on Twitter Track topics that are important to you
Stevenage, 22 February, 2017: Apollo Therapeutics (‘Apollo’), the collaborative venture between three world-leading UK universities and three global pharmaceutical companies, has invested in and launched the first of its drug discovery programmes in collaboration with academics at each of its partner universities.
Apollo Therapeutics was established in January 2016 by AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation and the technology transfer offices of Imperial College London, University College London and the University of Cambridge. It supports the translation of ground-breaking academic science from within these universities into innovative new drug discovery programmes and potential new medicines for a broad range of diseases.
After evaluating initial opportunities across all three universities, Apollo has approved funding for and launched its first four drug discovery projects:
These initial projects represent novel and compelling drug discovery projects, emerging from academic research in areas of high medical need for which Apollo’s Drug Discovery Team saw a clear route to value creation. A total of £8.5m has been committed in milestoned project plans.Two further projects are currently being finalised, with multiple others in the evaluation process across all three academic institutions.
The recruitment of the Drug Discovery Team Project Directors is now complete with Dr Paul Hamblin, Dr Darren Cawkill and Dr Nadine Clemo accepting positions under the leadership of CEO, Dr Richard Butt.
Bringing more than 60 years’ combined experience to running and delivering projects within industry, across a variety of technology platforms and therapy areas, the team is well positioned to work with academic scientists to identify drug targets and design innovative drug discovery programmes through key milestones for potential future licensing.
Apollo’s collaborative model is working well with its technology transfer partners – Cambridge Enterprise, Imperial Innovations and UCL Business – providing valuable support in sourcing opportunities from within their respective academic institutions. Industry partners AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation are also contributing both expertise and internal resources to enable project evaluation and execution.
Dr Richard Butt, CEO of Apollo Therapeutics, commented:
“The diversity of these four initial projects illustrates the breadth and quality of opportunity we are seeing from our partner universities, both in disease area and therapeutic modality. The participation and support of all six partners is excellent, in the spirit of this collaborative venture and the unique Apollo model.”
Dr Ian Tomlinson, Chairman of Apollo Therapeutics commented:
“The level of engagement with both the academic community and industry players is enabling the Drug Discovery Team to deliver Apollo’s vision of funding novel therapeutics, sourced from the best of British academic research, accelerating them towards the clinic.“
About Apollo Therapeutics
Apollo Therapeutics is a collaborative venture between three world-leading UK universities (Imperial College London, UCL and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation). It provides committed translational funding and drug discovery expertise for novel therapeutics, sourced from the best of British academic research, accelerating them towards the clinic.
Apollo’s unique model provides quick, independent access to the resources to grow innovations and to champion the best of British academic research to industry. Apollo’s experienced team of industry scientists have a proven track record of therapeutic delivery and work in partnership with academics and industry partners, crafting each bespoke project to optimise the chances of long-term success.
Apollo Therapeutics aims to create the therapies of the future by partnering with the UK’s globally leading academic science base and UK based Pharma industry to have a real impact on patient treatments and outcomes.Instinctif Partners Sue Charles/Rozi Morris firstname.lastname@example.org +44 (0)20 7457 2020NEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...